0001493152-23-004422.txt : 20230213 0001493152-23-004422.hdr.sgml : 20230213 20230213121604 ACCESSION NUMBER: 0001493152-23-004422 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20230213 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230213 DATE AS OF CHANGE: 20230213 FILER: COMPANY DATA: COMPANY CONFORMED NAME: bioAffinity Technologies, Inc. CENTRAL INDEX KEY: 0001712762 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 465211056 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41463 FILM NUMBER: 23616078 BUSINESS ADDRESS: STREET 1: 22211 WEST INTERSTATE-10 STREET 2: SUITE 1206 CITY: SAN ANTONIO STATE: TX ZIP: 78257 BUSINESS PHONE: 210-698-5334 MAIL ADDRESS: STREET 1: 22211 WEST INTERSTATE-10 STREET 2: SUITE 1206 CITY: SAN ANTONIO STATE: TX ZIP: 78257 8-K 1 form8-k.htm
0001712762 false 0001712762 2023-02-13 2023-02-13 0001712762 BIAF:CommonStockParValue.007PerShareMember 2023-02-13 2023-02-13 0001712762 BIAF:TradeableWarrantsToPurchaseCommonStockMember 2023-02-13 2023-02-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

February 13, 2023

Date of Report (Date of earliest event reported)

 

BIOAFFINITY TECHNOLOGIES, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-41463   46-5211056

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification Number)

 

22211 W Interstate 10

Suite 1206

San Antonio, Texas 78257

(210) 698-5334

(Address of principal executive offices and Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

  ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
  ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
  ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
  ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $.007 per share   BIAF   The Nasdaq Stock Market LLC
Tradeable Warrants to purchase Common Stock   BIAFW   The Nasdaq Stock Market LLC

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 8.01. Other Events.

 

Recent Press Release

 

On February 13, 2023, the Company issued a press release announcing its commercialization team. The press release is filed as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

  Exhibit No.   Description
  99.1   Press Release of bioAffinity Technologies, Inc., dated February 13, 2023.
  104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  BIOAFFINITY TECHNOLOGIES, INC.
   
  By: /s/ Maria Zannes
    Maria Zannes
    President and Chief Executive Officer

 

Dated: February 13, 2023

 

 

 

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

  News Release

 

For Immediate Release

 

bioAffinity Technologies Appoints Julie Anne Overton Director of Corporate Communications

 

Company enlists Havas Health & You, Trinity Life Sciences to help build
CyPath® Lung brand

 

SAN ANTONIO, TX – Feb. 13, 2023 – bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) today announced its commercialization team, including the addition of Julie Anne Overton, a veteran of print and broadcast journalism, corporate communications and federal public affairs, as bioAffinity Technologies’ Director of Communications, and the marketing and advertising firms of Havas Health & You and Trinity Life Sciences to help build the CyPath® Lung brand and position it for success in the cancer diagnostics sector.

 

CyPath® Lung is a non-invasive test that detects early-stage lung cancer by automated flow cytometry and machine learning. “CyPath® Lung has the potential to change the paradigm for the detection of early-stage lung cancer, and we have selected a team that can build our brand with intention and establish a genuine connection with physicians and patients who put their trust in us,” bioAffinity Technologies President and CEO Maria Zannes said. “To that end, in addition to hiring Julie Anne, we have engaged firms with excellent credentials in the healthcare and biotech industries who will bring creativity, purpose and strategic thinking to our story.”

 

Havas Health & You, the world’s largest global health network, is focused on promoting healthy living decisions across the entire health ecosystem. The firm is creating the branding and broader marketing strategy to align with the need for a patient-friendly diagnostic that gives physicians another tool to assess the potential or presence of lung cancer in their high-risk patients.

 

“Working with partners that create innovative solutions for physicians and the patients they serve aligns directly with our network’s focus on human purpose,” said Jeff Hoffman, Chief Development Officer and Partner at Havas Health & You. “We’re so excited to work with bioAffinity during this next step of their journey as a company, and I can’t think of a more meaningful way to start our partnership with Trinity Life Sciences than through our work on this project together.”

 

 

 

 

Trinity Life Sciences, a trusted strategic commercialization partner providing evidence-based solutions for the life sciences, is providing advisory services, insights and analytics to bioAffinity Technologies’ marketing strategy for CyPath® Lung.

 

“We are delighted to partner with bioAffinity on their commercialization of CyPath®, an accurate, non-invasive and cost-effective method of detecting lung cancer early,” said Rich Caligaris, Managing Director, Trinity Life Sciences. “Trinity’s extensive commercialization experience will support bioAffinity’s efforts to get this novel flow cytometry test to patients in need as effectively and quickly as possible. With our over 25-year history of offering evidence-based solutions and commitment to a greater purpose, we are honored to help see CyPath® through to its next phase of growth.”

 

Overton is a senior communications executive with expertise in communication principles, strategic planning and achieving organizational goals in a competitive environment. “I am honored to join bioAffinity Technologies at an exciting time in the Company’s history, and I look forward to partnering with Havas and Trinity to introduce physicians, patients and investors to the proprietary technology behind our CyPath® Lung test for the detection of early-stage lung cancer,” Ms. Overton said.

 

Prior to joining bioAffinity Technologies, Ms. Overton managed a comprehensive public affairs program for the USDA Forest Service. She began her career as a print and broadcast journalist, including more than a decade as a producer at the Washington, DC, bureau of CBS News. Prior to covering the Congress for CBS News, she served as Press Secretary for the late Congressman Charles Wilson (D-TX). She later joined Security Capital Group, a $24 billion global real estate operating company that was subsequently acquired by GE Capital, and served as Director of Communications and Investor Relations for a family of venture capital funds.

 

bioAffinity Technologies is implementing a regional rollout of CyPath® Lung, a noninvasive test for the early detection of lung cancer, in partnership with Precision Pathology Services, a commercial clinical laboratory. In a recent clinical trial, CyPath® Lung showed 92% sensitivity and 87% specificity in high-risk patients who had nodules smaller than 20 millimeters or no nodules in the lung, with an area under the ROC curve of 94%. CyPath® Lung uses automated flow cytometry developed with machine learning to analyze patient samples to reliably predict the presence of lung cancer.

 

About bioAffinity Technologies, Inc.

 

bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung, and targeted cancer treatment. The Company’s first product, CyPath® Lung, is a non-invasive test that has shown high sensitivity and specificity for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Services. OncoSelect Therapeutics, LLC, a subsidiary of bioAffinity Technologies, is advancing its discoveries shown in vitro to kill cancer cells without harm to normal cells. Research and optimization of the Company’s platform technologies are conducted in its laboratories at The University of Texas at San Antonio.

 

 

 

 

About Havas Health & You

 

Havas Health & You unites Havas Life, Health4Brands (H4B), Lynx, Red Havas and Havas Health Plus, all wholly owned health and communications networks, with the consumer health businesses and practices of Havas Creative Group. The network’s approach is centered around Human Purpose and has the talent, tenacity, and technology that health companies, brands and people need to thrive in today’s world. For more information, go to www.HavasHealthandYou.com.

 

About Trinity Life Sciences

 

Trinity Life Sciences is a trusted strategic commercialization partner, providing evidence-based solutions for the life sciences. With 25 years of experience, Trinity is committed to revolutionizing the commercial model by providing exceptional levels of service, powerful tools and data-driven insights. Trinity’s range of products and solutions includes industry-leading benchmarking solutions, powered by TGaS Advisors. To learn more about how Trinity is elevating life sciences and driving evidence to action, visit trinitylifesciences.com.

 

Forward-Looking Statements

 

This press release contains forward-looking statements, including statements regarding the anticipated use of proceeds from the Company’s offering of common shares. Forward-looking statements can be identified by words such as “believes,” “expects,” “estimates,” “intends,” “may,” “plans,” “will” and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.

 

# # #

 

Company Contact:

Julie Anne Overton, Director of Communications
jao@bioaffinitytech.com
505-577-0918

 

 

 

 GRAPHIC 3 ex99-1_001.jpg begin 644 ex99-1_001.jpg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end EX-101.SCH 4 biaf-20230213.xsd INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 5 biaf-20230213_def.xml INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 6 biaf-20230213_lab.xml INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Class of Stock [Axis] Common Stock, par value $.007 per share Tradeable Warrants to purchase Common Stock Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 7 biaf-20230213_pre.xml INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 8 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Cover
Feb. 13, 2023
Document Type 8-K
Amendment Flag false
Document Period End Date Feb. 13, 2023
Entity File Number 001-41463
Entity Registrant Name BIOAFFINITY TECHNOLOGIES, INC.
Entity Central Index Key 0001712762
Entity Tax Identification Number 46-5211056
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 22211 W Interstate 10
Entity Address, Address Line Two Suite 1206
Entity Address, City or Town San Antonio
Entity Address, State or Province TX
Entity Address, Postal Zip Code 78257
City Area Code (210)
Local Phone Number 698-5334
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Common Stock, par value $.007 per share  
Title of 12(b) Security Common Stock, par value $.007 per share
Trading Symbol BIAF
Security Exchange Name NASDAQ
Tradeable Warrants to purchase Common Stock  
Title of 12(b) Security Tradeable Warrants to purchase Common Stock
Trading Symbol BIAFW
XML 9 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001712762 2023-02-13 2023-02-13 0001712762 BIAF:CommonStockParValue.007PerShareMember 2023-02-13 2023-02-13 0001712762 BIAF:TradeableWarrantsToPurchaseCommonStockMember 2023-02-13 2023-02-13 iso4217:USD shares iso4217:USD shares 0001712762 false 8-K 2023-02-13 BIOAFFINITY TECHNOLOGIES, INC. DE 001-41463 46-5211056 22211 W Interstate 10 Suite 1206 San Antonio TX 78257 (210) 698-5334 false false false false true Common Stock, par value $.007 per share BIAF NASDAQ Tradeable Warrants to purchase Common Stock BIAFW NASDAQ false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 3 24 1 false 2 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://bioaffinitytech.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm biaf-20230213.xsd biaf-20230213_def.xml biaf-20230213_lab.xml biaf-20230213_pre.xml ex99-1.htm http://xbrl.sec.gov/dei/2022 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 1, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 27 }, "contextCount": 3, "dts": { "definitionLink": { "local": [ "biaf-20230213_def.xml" ] }, "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "biaf-20230213_lab.xml" ] }, "presentationLink": { "local": [ "biaf-20230213_pre.xml" ] }, "schema": { "local": [ "biaf-20230213.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 65, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 2, "memberStandard": 0, "nsprefix": "BIAF", "nsuri": "http://bioaffinitytech.com/20230213", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2023-02-13to2023-02-13", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://bioaffinitytech.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2023-02-13to2023-02-13", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 2, "tag": { "BIAF_CommonStockParValue.007PerShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock, par value $.007 per share" } } }, "localname": "CommonStockParValue.007PerShareMember", "nsuri": "http://bioaffinitytech.com/20230213", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "domainItemType" }, "BIAF_TradeableWarrantsToPurchaseCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Tradeable Warrants to purchase Common Stock" } } }, "localname": "TradeableWarrantsToPurchaseCommonStockMember", "nsuri": "http://bioaffinitytech.com/20230213", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "stringItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 16 0001493152-23-004422-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-004422-xbrl.zip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

C\_?GY[CY7^* M%VDH770@3M2D)U[^T!&[.[L_U$\;=BZ:9MX1IVG0$]^]'XR.!__8%T>G@Y,# M_OGQ>RA$*)="IJDIH""AT%"I $:N;* AD-_9T-NM7,FD(W0:Q$6HH1AYI(0, M0TV?$D+;4'9Z;3H+[NU0YG8N> MR)!#)$>_3[5-' UMFEF[5=L9#_@#IL;+?-;2>+;,."]6G4,EK'!%@.D$_$[D\3IN\?H>4?],O?(D:ZBI2DW9U M"FW15VR6J1R"#2,"_$3C:%:O;$BS@D#;]S1Q&4EK0F,SD0%A9-:AE$,L7J_%Q: M&>I9PII&#_PV2ZO>L%=O. N%V7%$AW NH$U+02CA3XL7VRVO^3#R4KL7&BX* M,$ [P0+T".*1,&D78?1,I06=,#" $;\''I%%2Z>!1B489+!>14'+(C(B*TB\ M2F/S%CI"1E*XS@O+DA&;(Y\+JYP.50E)PS?GXIVT6HK_!1+B8R=U6 MX;/R9 M5!H2!*YPCRQ<6X*)%?QU:KFH= :YA26$\$G45:#B&*NV6X%5H;^1VK(C!I= M6N5Q4N/. A)8B)-9VC6=>*'C&/*D53$'9#''Z3H0!/#3^9%X&UHT U#F4)E+ MQFO#]^ $\M>*9YGN'AXN&"WT6[=#,_HPA?&QF'IIYR(L0-"BUEL)K!3KPTB M53E>N^P0MDQ-4#AH%%0OLR8Q[+'\>TL10Q'P:Z@">"YVG($USEL_*9I5[58Y MIPJ,6[I<)3TQQJ>DH#2]5Z?2N;/%5AZ1738P:N4G2Q5;DF*QT+V"T\A4D=(# M3F1EJMTIM#<-XV7#:R&D()N: 23=NH4;3 )S-H:Q2CJGW'4,P^09#)C\+,%4 M$T:]+0$/(CV+NE:[RQHPGOWCUZ C/&9^A,Y"3]HMC^#2YJFRKO0-I&<*-Y6: M.>$77(B)"Q_MD=Y!R+07QT!Y6B^ ZZQ2L1R)4F4QL6FTV[ M!:N)"ARA@LK:2Q#8B[^K*8(\,YWR(8>15E-QK.8J-EE";N(U6+.SQZ?]4R_O==B41-<'^-NMNER_'T\?AU[DLZH!+)V:PW)B)G@;$$U0^4;I$>%BP1M<\VQ MD)I3SA"H[D12'+;NMLA/Q;2.J]?QN%@.EN%<.X3?E*[;N?8OI(X*/M[1R53& M2TKH"9\_1VO<$HK1)NZ@&)[#GZ\8_B#8ICPN5#'=+W0%5UKITPVG;ZJ8]:8. M$FEUZY62UT>('Q1T^9UUTH&4"2%^WD5,0XGT'+M)X)5-2/.5&3XTIQDWF4L?;N7E2=94IRQ/X M%-<5669LWA34:J(I=#UG.T&T449+!L':=>+$TR]F%3\B/>#\1/(D7C@Q3))$ M]ENA@\N8@RO$ATY/8M43'ZNH$M-;L?NZNX2DD%QP)DWB1,BH[)W@X*\C273. MD20E-6+&,;"M8U%B#22G:":%LPEK]M"IC;QA%8OA56)M.5S,(BQ.VYI9L\BC M/V<4]CA-O^2]VRUF 9&<:F.OD]GJ2@4%ISPE'Y0QTTS)T/JKS)<'.HMIQ963 MRF*9IC5/'2!+X:3?V!GB>V](2(]G1L9(>(BJXB0!?H+75.E<6Y.2%M8V>BID M(AI*]\E@V";G0QF/3'T:PVD*)%*Q5V5AJK;1TD0ZWK9.16S,);FHA;1--*1I M6!8^DVK2Z:37:6Y-6 35DEA9V7-]#903]%*C :<*UH#X2GD-V3_Y>9AXA.% MI,C3D7<1\0P97\2&5J#Y#LA754^90'RVNH>WN@NKJ;N@U%S2ILUEL.8%)>3, MF+0F"[$J\IY)K%>82)EF5J[H\5]&QP-Q F.!DHQ\&-<3(^++U(PH;Z*NB,$E M=H!@X,ZR5]ZLJ'&>SCFV)!)/AJJ:@0V V0;:P4>)1#V=<87M>-@1DP*NI.! MX6A$@G.]=HNEPE0_N:V*TQN:%'['^7"U>AOP$BE/J;!;O. W1BJPWH3JT-:7 M__T,1*,,(]@#[NJCCAT$^MUQ=_S/[[TPZ%U<"MT()L5V)P\1<%8@FA&_XVMVZR6[2NL9\]?= M0!/ZVX,]@0IZ$%[0HNY\*+#CY7 6_(H@U:6$,DYE0^9O*,]!$/@7U1*Q> MR*TFG;[](,AP:5H>Z^^[=WIB0M'$<>FFFCHR5E5EA6OET?9)7!&_7M-'\,K MDZ9PI&"1FR) >^=744R#"E,4&Z](MB$V;(4J-WUT+HD) BT0J1&DF;Q!1"VR3*A MR*E:2K!0OIY30NTSF_$MV<@4P5Q>QE+Y)A0MW<%=71S43T$H2Z$>X/,&S#8A M]DN2B+N1$#OR?)\/T:0XJ[U%NW5< ^&8MOG=V?'X>XJ$[O)"B(/3P(RX.^+L;$@^B@(LC3OR),=FDR1AA7.<@3&7> A,JKHYX(WR!!SAI194)O("--R$'2ASW$9- $&T0L9),A\6PP M9+>DG^T64N4<-Y"LO\+A*6[O/I:WGTM9C,8R'B8QN[S9XW%\W>\K!SX;N+60T M&B%!25E2[:-37LJK(VJ;6-VZL[!LL_.^Z$PZM:2X#-$?=T6 M!Y_#?$&30^??[G(H2Z2[KP551JG/;MJHY:Y*Q-J51="R&F[5O)Q8_UX1U UB M+#&ABBF-:>SK*E!96>***>EA1"N;*7 LU"6.MRH==3Y+#&4N>R&A!]IW6O1 M$]?KTI;;X?E+*IP?>AA:G=N3]$QR<2OVLALKR5N:X(P1I6;>H/&;)"><\9M&4$]*RN>>]UR3M4V+K^WRK2^)RDY\27.[IDQO@-V1+4,8B8>_.N2?P+J"KD9L$@E1!CJ0E=#W9N!_B3X! @K_' MHJ?:%\ 0%H54'R.NQ%55_HF*-1!S]MQN5<]QA\2ZWQC W]X) M;SQ.Y/+Z(VI5N/$>=?94CQAC-6Y06G(8=!L>/+F>RQ'IS$>IGN)QRI^M)T9T MN,WWQ"2/]UV0XU16@$Z\CR[K?64GN;K2+J\JJ]S-P();S>7;N!*NQG(LS<6" M>@XCI@57!&];A5@K^MI$25]R,V!3Y9B+DNPR%)57M'LD%Q/JY:J^NE1D(159[YR7MN ]$09 (:CP MTVX1PUCUZ0_SH/_<"#..4UR M^^*,^HV>:?'/T.(/1%P_O'YNTU]\\W\"COY2W+\ 4$L#!!0 ( %B3598 MY)2D3Q, !"@ + 9F]R;3@M:RYH=&WM'6M7XKKVNVOY'W*Y]]SEK"/0 M%A!!A[MX.O@" 4?'+Z[0!HB4MO8AX*^_.VD+%,J,S@%%AS-G"33)SGYE9V?O M)#W^WVB@HB=B6E37OD;$F!!!1)-UA6K=KQ''[D0/(__+[>X<]VRH!W4UZVND M9]M&-AX?#H>Q82*FF]VXF,EDXB-6)^)6RHY"ZTF"(,9O+\Z;56M?VJ MU-*3DIC^&1YNC4F#T;*Z(L,9*"2WA<;YM+H=7G]:-6Z;6+,ZNCG -LB004I% M!2DJ'

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end